![](https://endpts.com/wp-content/uploads/2024/05/Ameet-Mallik-Mohamed-Zaki-ADC-Therapeutics-tile.jpg)
ADC Therapeutics CEO Ameet Mallik (L) and CMO Mohamed Zaki
ADC Therapeutics reveals topline Zynlonta data, $105M stock offering
ADC Therapeutics announced a $105 million offering after sharing what it called positive topline data from a Phase 2 trial of …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.